Search Results for: Diabetes

3097 interactions found:

Symbols Name 1 Name 2
Pathways 1
Pathways 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
PPARG and NCOA1 peroxisome proliferator-activated receptor gamma nuclear receptor coactivator 1
  • PPARA activates gene expression
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Metabolism of lipids and lipoproteins
  • Generic Transcription Pathway
  • Transcriptional regulation of white adipocyte differentiation
  • Nuclear Receptor transcription pathway
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • PPARA activates gene expression
  • Bile acid and bile salt metabolism
  • Defective CYP2R1 causes Rickets vitamin D-dependent 1B (VDDR1B)
  • Organelle biogenesis and maintenance
  • Metabolism of lipids and lipoproteins
  • Metabolic disorders of biological oxidation enzymes
  • Phase 1 - Functionalization of compounds
  • Defective CYP27B1 causes Rickets vitamin D-dependent 1A (VDDR1A)
  • RORA activates circadian gene expression
  • Regulation of cholesterol biosynthesis by SREBP (SREBF)
  • Defective CYP26C1 causes Focal facial dermal dysplasia 4 (FFDD4)
  • Generic Transcription Pathway
  • Defective CYP2U1 causes Spastic paraplegia 56, autosomal recessive (SPG56)
  • Cytochrome P450 - arranged by substrate type
  • Endogenous sterols
  • Transcriptional regulation of white adipocyte differentiation
  • Biological oxidations
  • Synthesis of bile acids and bile salts
  • Orphan transporters
  • Defective FMO3 causes Trimethylaminuria (TMAU)
  • Defective TBXAS1 causes Ghosal hematodiaphyseal dysplasia (GHDD)
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Defective CYP11A1 causes Adrenal insufficiency, congenital, with 46,XY sex reversal (AICSR)
  • Defective CYP27A1 causes Cerebrotendinous xanthomatosis (CTX)
  • Defective CYP11B1 causes Adrenal hyperplasia 4 (AH4)
  • Recycling of bile acids and salts
  • Defective CYP26B1 causes Radiohumeral fusions with other skeletal and craniofacial anomalies (RHFCA)
  • REV-ERBA represses gene expression
  • Defective CYP1B1 causes Glaucoma
  • Defective CYP17A1 causes Adrenal hyperplasia 5 (AH5)
  • Mitochondrial biogenesis
  • Defective CYP7B1 causes Spastic paraplegia 5A, autosomal recessive (SPG5A) and Congenital bile acid synthesis defect 3 (CBAS3)
  • Defective CYP19A1 causes Aromatase excess syndrome (AEXS)
  • Defective CYP4F22 causes Ichthyosis, congenital, autosomal recessive 5 (ARCI5)
  • Defective CYP24A1 causes Hypercalcemia, infantile (HCAI)
  • Synthesis of bile acids and bile salts via 27-hydroxycholesterol
  • Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol
  • Defective MAOA causes Brunner syndrome (BRUNS)
  • Defective CYP11B2 causes Corticosterone methyloxidase 1 deficiency (CMO-1 deficiency)
  • YAP1- and WWTR1 (TAZ)-stimulated gene expression
  • Activation of gene expression by SREBF (SREBP)
  • Defective CYP21A2 causes Adrenal hyperplasia 3 (AH3)
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • Transcriptional activation of mitochondrial biogenesis
  • BMAL1:CLOCK,NPAS2 activates circadian gene expression
  • Icosapent
  • Troglitazone
  • Mesalazine
  • Indomethacin
  • Rosiglitazone
  • Nateglinide
  • Sulfasalazine
  • Repaglinide
  • Telmisartan
  • Balsalazide
  • Ibuprofen
  • Glipizide
  • Pioglitazone
  • Mitiglinide
  • Bezafibrate
  • (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
  • 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
  • (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
  • 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
  • (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
  • (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
  • (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
  • (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
  • difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
  • (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
  • 3-(5-methoxy-1H-indol-3-yl)propanoic acid
  • 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
  • (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
  • 2-chloro-5-nitro-N-phenylbenzamide
  • (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
  • 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
  • 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
  • (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
  • 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
  • (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
  • ALEGLITAZAR
PPARG and PRKCA peroxisome proliferator-activated receptor gamma protein kinase C, alpha
  • PPARA activates gene expression
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Metabolism of lipids and lipoproteins
  • Generic Transcription Pathway
  • Transcriptional regulation of white adipocyte differentiation
  • Nuclear Receptor transcription pathway
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • Ca-dependent events
  • Signaling by GPCR
  • CaM pathway
  • Signaling by FGFR in disease
  • Phospholipase C-mediated cascade
  • Integration of energy metabolism
  • Mitotic Prophase
  • Signaling by Wnt
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Regulation of KIT signaling
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Response to elevated platelet cytosolic Ca2+
  • G alpha (z) signalling events
  • Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
  • Signaling by PDGF
  • Calmodulin induced events
  • DAP12 interactions
  • Regulation of mRNA stability by proteins that bind AU-rich elements
  • Opioid Signalling
  • Diseases associated with visual transduction
  • EGFR interacts with phospholipase C-gamma
  • Signaling by ERBB2
  • Signaling by EGFR
  • Syndecan interactions
  • GPCR downstream signaling
  • Signaling by VEGF
  • Calmodulin induced events
  • Downstream signal transduction
  • WNT5A-dependent internalization of FZD4
  • Signaling by EGFR in Cancer
  • Platelet activation, signaling and aggregation
  • PCP/CE pathway
  • Transmission across Chemical Synapses
  • Trafficking of GluR2-containing AMPA receptors
  • Nuclear Envelope Breakdown
  • HuR stabilizes mRNA
  • DAG and IP3 signaling
  • M Phase
  • VEGFA-VEGFR2 Pathway
  • CaM pathway
  • Inactivation, recovery and regulation of the phototransduction cascade
  • EGFR Transactivation by Gastrin
  • VEGFR2 mediated cell proliferation
  • Downstream signaling of activated FGFR
  • The phototransduction cascade
  • Disinhibition of SNARE formation
  • Innate Immune System
  • Signalling by NGF
  • PLC beta mediated events
  • Regulation of insulin secretion
  • Depolymerisation of the Nuclear Lamina
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • G-protein mediated events
  • Non-integrin membrane-ECM interactions
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Trafficking of AMPA receptors
  • Cell Cycle, Mitotic
  • Signaling by FGFR
  • beta-catenin independent WNT signaling
  • Acetylcholine regulates insulin secretion
  • Visual phototransduction
  • Ca2+ pathway
  • PLC-gamma1 signalling
  • Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity
  • Icosapent
  • Troglitazone
  • Mesalazine
  • Indomethacin
  • Rosiglitazone
  • Nateglinide
  • Sulfasalazine
  • Repaglinide
  • Telmisartan
  • Balsalazide
  • Ibuprofen
  • Glipizide
  • Pioglitazone
  • Mitiglinide
  • Bezafibrate
  • (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
  • 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
  • (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
  • 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
  • (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
  • (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
  • (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
  • (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
  • difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
  • (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
  • 3-(5-methoxy-1H-indol-3-yl)propanoic acid
  • 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
  • (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
  • 2-chloro-5-nitro-N-phenylbenzamide
  • (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
  • 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
  • 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
  • (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
  • 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
  • (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
  • ALEGLITAZAR
  • Phosphatidylserine
  • Vitamin E
  • Ingenol Mebutate
  • Ellagic Acid
PPARG and SMARCD3 peroxisome proliferator-activated receptor gamma SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 3
  • PPARA activates gene expression
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Metabolism of lipids and lipoproteins
  • Generic Transcription Pathway
  • Transcriptional regulation of white adipocyte differentiation
  • Nuclear Receptor transcription pathway
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • PPARA activates gene expression
  • Organelle biogenesis and maintenance
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Metabolism of lipids and lipoproteins
  • Chromatin organization
  • REV-ERBA represses gene expression
  • RORA activates circadian gene expression
  • Mitochondrial biogenesis
  • RMTs methylate histone arginines
  • Regulation of cholesterol biosynthesis by SREBP (SREBF)
  • Chromatin modifying enzymes
  • Generic Transcription Pathway
  • Transcriptional regulation of white adipocyte differentiation
  • YAP1- and WWTR1 (TAZ)-stimulated gene expression
  • Activation of gene expression by SREBF (SREBP)
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • Transcriptional activation of mitochondrial biogenesis
  • BMAL1:CLOCK,NPAS2 activates circadian gene expression
  • Orphan transporters
  • Icosapent
  • Troglitazone
  • Mesalazine
  • Indomethacin
  • Rosiglitazone
  • Nateglinide
  • Sulfasalazine
  • Repaglinide
  • Telmisartan
  • Balsalazide
  • Ibuprofen
  • Glipizide
  • Pioglitazone
  • Mitiglinide
  • Bezafibrate
  • (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
  • 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
  • (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
  • 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
  • (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
  • (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
  • (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
  • (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
  • difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
  • (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
  • 3-(5-methoxy-1H-indol-3-yl)propanoic acid
  • 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
  • (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
  • 2-chloro-5-nitro-N-phenylbenzamide
  • (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
  • 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
  • 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
  • (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
  • 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
  • (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
  • ALEGLITAZAR
PPARG and MAPK1 peroxisome proliferator-activated receptor gamma mitogen-activated protein kinase 1
  • PPARA activates gene expression
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Metabolism of lipids and lipoproteins
  • Generic Transcription Pathway
  • Transcriptional regulation of white adipocyte differentiation
  • Nuclear Receptor transcription pathway
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • phospho-PLA2 pathway
  • Ca-dependent events
  • Signaling by FGFR in disease
  • Cellular Senescence
  • ERKs are inactivated
  • CREB phosphorylation through the activation of Ras
  • Signaling by EGFRvIII in Cancer
  • Toll Like Receptor TLR1:TLR2 Cascade
  • Toll Like Receptor 5 (TLR5) Cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • MyD88 dependent cascade initiated on endosome
  • SOS-mediated signalling
  • Fcgamma receptor (FCGR) dependent phagocytosis
  • SHC-mediated signalling
  • Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
  • Regulation of actin dynamics for phagocytic cup formation
  • TRIF-mediated TLR3/TLR4 signaling
  • Senescence-Associated Secretory Phenotype (SASP)
  • Signaling by VEGF
  • Signalling to RAS
  • Downstream signal transduction
  • Toll Like Receptor 3 (TLR3) Cascade
  • Interleukin-2 signaling
  • Platelet activation, signaling and aggregation
  • Frs2-mediated activation
  • Transmission across Chemical Synapses
  • Axon guidance
  • IRS-mediated signalling
  • L1CAM interactions
  • Oncogene Induced Senescence
  • VEGFA-VEGFR2 Pathway
  • Activated TLR4 signalling
  • VEGFR2 mediated cell proliferation
  • GRB2 events in ERBB2 signaling
  • RSK activation
  • Activation of NMDA receptor upon glutamate binding and postsynaptic events
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • MyD88:Mal cascade initiated on plasma membrane
  • NCAM signaling for neurite out-growth
  • Signalling to p38 via RIT and RIN
  • RAF/MAP kinase cascade
  • Innate Immune System
  • Signaling by Insulin receptor
  • ERKs are inactivated
  • Signal transduction by L1
  • Insulin receptor signalling cascade
  • PLC beta mediated events
  • IRS-related events
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • SHC-related events
  • G-protein mediated events
  • Signaling by FGFR
  • Thrombin signalling through proteinase activated receptors (PARs)
  • ARMS-mediated activation
  • Toll-Like Receptors Cascades
  • Toll Like Receptor 10 (TLR10) Cascade
  • Signal attenuation
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • ERK/MAPK targets
  • MAPK targets/ Nuclear events mediated by MAP kinases
  • Signaling by GPCR
  • Mitotic Prophase
  • Golgi Cisternae Pericentriolar Stack Reorganization
  • FCERI mediated MAPK activation
  • Signaling by SCF-KIT
  • SHC1 events in ERBB2 signaling
  • DAP12 signaling
  • Toll Like Receptor 9 (TLR9) Cascade
  • ERK/MAPK targets
  • Negative regulation of FGFR signaling
  • Signaling by PDGF
  • DAP12 interactions
  • Opioid Signalling
  • SHC-related events triggered by IGF1R
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Toll Like Receptor 2 (TLR2) Cascade
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by Interleukins
  • SHC1 events in ERBB4 signaling
  • Toll Like Receptor 4 (TLR4) Cascade
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • Signaling by Leptin
  • Growth hormone receptor signaling
  • Signalling to ERKs
  • Prolonged ERK activation events
  • ERK activation
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • IGF1R signaling cascade
  • Recycling pathway of L1
  • M Phase
  • Toll Like Receptor TLR6:TLR2 Cascade
  • IRS-related events triggered by IGF1R
  • Activation of the AP-1 family of transcription factors
  • MyD88 cascade initiated on plasma membrane
  • ERK activation
  • Downstream signaling of activated FGFR
  • Advanced glycosylation endproduct receptor signaling
  • Post NMDA receptor activation events
  • Signalling by NGF
  • SOS-mediated signalling
  • MAP kinase activation in TLR cascade
  • SHC-mediated signalling
  • Cytokine Signaling in Immune system
  • Cellular response to heat stress
  • Regulation of HSF1-mediated heat shock response
  • NGF signalling via TRKA from the plasma membrane
  • MyD88-independent cascade
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Cell Cycle, Mitotic
  • ERK2 activation
  • SHC1 events in EGFR signaling
  • FRS2-mediated cascade
  • IRS-mediated signalling
  • Oxidative Stress Induced Senescence
  • ERK2 activation
  • Nuclear Events (kinase and transcription factor activation)
  • Icosapent
  • Troglitazone
  • Mesalazine
  • Indomethacin
  • Rosiglitazone
  • Nateglinide
  • Sulfasalazine
  • Repaglinide
  • Telmisartan
  • Balsalazide
  • Ibuprofen
  • Glipizide
  • Pioglitazone
  • Mitiglinide
  • Bezafibrate
  • (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
  • 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
  • (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
  • 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
  • (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
  • (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
  • (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
  • (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
  • difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
  • (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
  • 3-(5-methoxy-1H-indol-3-yl)propanoic acid
  • 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
  • (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
  • 2-chloro-5-nitro-N-phenylbenzamide
  • (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
  • 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
  • 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
  • (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
  • 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
  • (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
  • ALEGLITAZAR
  • Isoproterenol
  • Arsenic trioxide
  • Olomoucine
  • Phosphonothreonine
  • Purvalanol
  • SB220025
  • N,N-DIMETHYL-4-(4-PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
  • N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDE
  • (S)-N-(1-(3-CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
  • (3R,5Z,8S,9S,11E)-8,9,16-TRIHYDROXY-14-METHOXY-3-METHYL-3,4,9,10-TETRAHYDRO-1H-2-BENZOXACYCLOTETRADECINE-1,7(8H)-DIONE
  • 5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZIN-3-AMINE
  • (1aR,8S,13S,14S,15aR)-5,13,14-trihydroxy-3-methoxy-8-methyl-8,9,13,14,15,15a-hexahydro-6H-oxireno[k][2]benzoxacyclotetradecine-6,12(1aH)-dione
  • [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
  • 4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-3H-IMIDAZOL-4-YL]-PYRIDINE
PPARG and MAPK8 peroxisome proliferator-activated receptor gamma mitogen-activated protein kinase 8
  • PPARA activates gene expression
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Metabolism of lipids and lipoproteins
  • Generic Transcription Pathway
  • Transcriptional regulation of white adipocyte differentiation
  • Nuclear Receptor transcription pathway
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • Cellular Senescence
  • Activation of BH3-only proteins
  • FCERI mediated MAPK activation
  • Toll Like Receptor TLR6:TLR2 Cascade
  • Activation of BMF and translocation to mitochondria
  • Activated TLR4 signalling
  • Toll Like Receptor TLR1:TLR2 Cascade
  • Activation of the AP-1 family of transcription factors
  • MyD88 cascade initiated on plasma membrane
  • Toll Like Receptor 5 (TLR5) Cascade
  • Programmed Cell Death
  • MyD88 dependent cascade initiated on endosome
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • MyD88:Mal cascade initiated on plasma membrane
  • Toll Like Receptor 9 (TLR9) Cascade
  • Intrinsic Pathway for Apoptosis
  • JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
  • Innate Immune System
  • Signalling by NGF
  • Cell death signalling via NRAGE, NRIF and NADE
  • TRIF-mediated TLR3/TLR4 signaling
  • MAP kinase activation in TLR cascade
  • p75 NTR receptor-mediated signalling
  • MyD88-independent cascade
  • Toll Like Receptor 2 (TLR2) Cascade
  • Toll-Like Receptors Cascades
  • Toll Like Receptor 10 (TLR10) Cascade
  • DSCAM interactions
  • NRIF signals cell death from the nucleus
  • Oxidative Stress Induced Senescence
  • Activation of BIM and translocation to mitochondria
  • Toll Like Receptor 3 (TLR3) Cascade
  • Toll Like Receptor 4 (TLR4) Cascade
  • NRAGE signals death through JNK
  • Fc epsilon receptor (FCERI) signaling
  • MAPK targets/ Nuclear events mediated by MAP kinases
  • Icosapent
  • Troglitazone
  • Mesalazine
  • Indomethacin
  • Rosiglitazone
  • Nateglinide
  • Sulfasalazine
  • Repaglinide
  • Telmisartan
  • Balsalazide
  • Ibuprofen
  • Glipizide
  • Pioglitazone
  • Mitiglinide
  • Bezafibrate
  • (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
  • 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
  • (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
  • 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
  • (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
  • (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
  • (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
  • (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
  • difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
  • (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
  • 3-(5-methoxy-1H-indol-3-yl)propanoic acid
  • 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
  • (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
  • 2-chloro-5-nitro-N-phenylbenzamide
  • (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
  • 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
  • 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
  • (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
  • 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
  • (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
  • ALEGLITAZAR
PPARG and ZBTB3 peroxisome proliferator-activated receptor gamma zinc finger and BTB domain containing 3
  • PPARA activates gene expression
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Metabolism of lipids and lipoproteins
  • Generic Transcription Pathway
  • Transcriptional regulation of white adipocyte differentiation
  • Nuclear Receptor transcription pathway
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • Icosapent
  • Troglitazone
  • Mesalazine
  • Indomethacin
  • Rosiglitazone
  • Nateglinide
  • Sulfasalazine
  • Repaglinide
  • Telmisartan
  • Balsalazide
  • Ibuprofen
  • Glipizide
  • Pioglitazone
  • Mitiglinide
  • Bezafibrate
  • (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
  • 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
  • (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
  • 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
  • (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
  • (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
  • (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
  • (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
  • difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
  • (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
  • 3-(5-methoxy-1H-indol-3-yl)propanoic acid
  • 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
  • (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
  • 2-chloro-5-nitro-N-phenylbenzamide
  • (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
  • 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
  • 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
  • (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
  • 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
  • (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
  • ALEGLITAZAR
PPARG and MAP2K1 peroxisome proliferator-activated receptor gamma mitogen-activated protein kinase kinase 1
  • PPARA activates gene expression
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Metabolism of lipids and lipoproteins
  • Generic Transcription Pathway
  • Transcriptional regulation of white adipocyte differentiation
  • Nuclear Receptor transcription pathway
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • MEK activation
  • FCERI mediated MAPK activation
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • SHC1 events in ERBB2 signaling
  • Toll Like Receptor TLR1:TLR2 Cascade
  • DAP12 signaling
  • Uptake and actions of bacterial toxins
  • Toll Like Receptor 5 (TLR5) Cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • MyD88 dependent cascade initiated on endosome
  • Toll Like Receptor 9 (TLR9) Cascade
  • SOS-mediated signalling
  • Uptake and function of anthrax toxins
  • SHC-mediated signalling
  • Signaling by PDGF
  • DAP12 interactions
  • TRIF-mediated TLR3/TLR4 signaling
  • ERK1 activation
  • SHC-related events triggered by IGF1R
  • GRB2 events in EGFR signaling
  • ERK1 activation
  • Signaling by ERBB4
  • Toll Like Receptor 2 (TLR2) Cascade
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by Interleukins
  • SHC1 events in ERBB4 signaling
  • Signaling by VEGF
  • Toll Like Receptor 3 (TLR3) Cascade
  • Toll Like Receptor 4 (TLR4) Cascade
  • Signalling to RAS
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • Interleukin-1 signaling
  • Interleukin-2 signaling
  • Frs2-mediated activation
  • Signaling by Leptin
  • Signalling to ERKs
  • Prolonged ERK activation events
  • ERK activation
  • Axon guidance
  • IRS-mediated signalling
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • L1CAM interactions
  • IGF1R signaling cascade
  • Toll Like Receptor TLR6:TLR2 Cascade
  • VEGFA-VEGFR2 Pathway
  • Activated TLR4 signalling
  • IRS-related events triggered by IGF1R
  • MyD88 cascade initiated on plasma membrane
  • VEGFR2 mediated cell proliferation
  • GRB2 events in ERBB2 signaling
  • ERK activation
  • RAF phosphorylates MEK
  • Downstream signaling of activated FGFR
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • MyD88:Mal cascade initiated on plasma membrane
  • NCAM signaling for neurite out-growth
  • RAF/MAP kinase cascade
  • Signalling to p38 via RIT and RIN
  • Signaling by Insulin receptor
  • Innate Immune System
  • Signalling by NGF
  • Signal transduction by L1
  • Insulin receptor signalling cascade
  • SOS-mediated signalling
  • MAP kinase activation in TLR cascade
  • SHC-mediated signalling
  • Cytokine Signaling in Immune system
  • IRS-related events
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • SHC-related events
  • MyD88-independent cascade
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by FGFR
  • ARMS-mediated activation
  • Toll-Like Receptors Cascades
  • Toll Like Receptor 10 (TLR10) Cascade
  • SHC1 events in EGFR signaling
  • IRS-mediated signalling
  • FRS2-mediated cascade
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • Icosapent
  • Troglitazone
  • Mesalazine
  • Indomethacin
  • Rosiglitazone
  • Nateglinide
  • Sulfasalazine
  • Repaglinide
  • Telmisartan
  • Balsalazide
  • Ibuprofen
  • Glipizide
  • Pioglitazone
  • Mitiglinide
  • Bezafibrate
  • (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
  • 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
  • (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
  • 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
  • (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
  • (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
  • (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
  • (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
  • difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
  • (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
  • 3-(5-methoxy-1H-indol-3-yl)propanoic acid
  • 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
  • (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
  • 2-chloro-5-nitro-N-phenylbenzamide
  • (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
  • 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
  • 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
  • (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
  • 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
  • (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
  • ALEGLITAZAR
  • K-252a
  • 5-Bromo-N-(2,3-Dihydroxypropoxy)-3,4-Difluoro-2-[(2-Fluoro-4-Iodophenyl)Amino]Benzamide
  • Bosutinib
  • (5S)-4,5-difluoro-6-[(2-fluoro-4-iodophenyl)imino]-N-(2-hydroxyethoxy)cyclohexa-1,3-diene-1-carboxamide
  • 2-[(2-chloro-4-iodophenyl)amino]-N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluorobenzamide
  • N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide
  • N-(5-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-1,3,4-oxadiazol-2-yl)ethane-1,2-diamine
  • 2-[(4-ETHYNYL-2-FLUOROPHENYL)AMINO]-3,4-DIFLUORO-N-(2-HYDROXYETHOXY)BENZAMIDE
  • Trametinib
PPARG and TNP1 peroxisome proliferator-activated receptor gamma transition protein 1 (during histone to protamine replacement)
  • PPARA activates gene expression
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Metabolism of lipids and lipoproteins
  • Generic Transcription Pathway
  • Transcriptional regulation of white adipocyte differentiation
  • Nuclear Receptor transcription pathway
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • Icosapent
  • Troglitazone
  • Mesalazine
  • Indomethacin
  • Rosiglitazone
  • Nateglinide
  • Sulfasalazine
  • Repaglinide
  • Telmisartan
  • Balsalazide
  • Ibuprofen
  • Glipizide
  • Pioglitazone
  • Mitiglinide
  • Bezafibrate
  • (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
  • 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
  • (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
  • 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
  • (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
  • (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
  • (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
  • (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
  • difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
  • (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
  • 3-(5-methoxy-1H-indol-3-yl)propanoic acid
  • 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
  • (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
  • 2-chloro-5-nitro-N-phenylbenzamide
  • (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
  • 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
  • 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
  • (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
  • 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
  • (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
  • ALEGLITAZAR
PPARG and CNOT1 peroxisome proliferator-activated receptor gamma CCR4-NOT transcription complex, subunit 1
  • PPARA activates gene expression
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Metabolism of lipids and lipoproteins
  • Generic Transcription Pathway
  • Transcriptional regulation of white adipocyte differentiation
  • Nuclear Receptor transcription pathway
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • Deadenylation of mRNA
  • Deadenylation-dependent mRNA decay
  • Icosapent
  • Troglitazone
  • Mesalazine
  • Indomethacin
  • Rosiglitazone
  • Nateglinide
  • Sulfasalazine
  • Repaglinide
  • Telmisartan
  • Balsalazide
  • Ibuprofen
  • Glipizide
  • Pioglitazone
  • Mitiglinide
  • Bezafibrate
  • (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
  • 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
  • (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
  • 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
  • (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
  • (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
  • (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
  • (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
  • difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
  • (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
  • 3-(5-methoxy-1H-indol-3-yl)propanoic acid
  • 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
  • (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
  • 2-chloro-5-nitro-N-phenylbenzamide
  • (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
  • 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
  • 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
  • (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
  • 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
  • (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
  • ALEGLITAZAR
PPARG and LRIF1 peroxisome proliferator-activated receptor gamma ligand dependent nuclear receptor interacting factor 1
  • PPARA activates gene expression
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Metabolism of lipids and lipoproteins
  • Generic Transcription Pathway
  • Transcriptional regulation of white adipocyte differentiation
  • Nuclear Receptor transcription pathway
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • Icosapent
  • Troglitazone
  • Mesalazine
  • Indomethacin
  • Rosiglitazone
  • Nateglinide
  • Sulfasalazine
  • Repaglinide
  • Telmisartan
  • Balsalazide
  • Ibuprofen
  • Glipizide
  • Pioglitazone
  • Mitiglinide
  • Bezafibrate
  • (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
  • 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
  • (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
  • 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
  • (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
  • (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
  • (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
  • (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
  • difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
  • (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
  • 3-(5-methoxy-1H-indol-3-yl)propanoic acid
  • 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
  • (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
  • 2-chloro-5-nitro-N-phenylbenzamide
  • (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
  • 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
  • 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
  • (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
  • 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
  • (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
  • ALEGLITAZAR
PPARG and NLK peroxisome proliferator-activated receptor gamma nemo-like kinase
  • PPARA activates gene expression
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Metabolism of lipids and lipoproteins
  • Generic Transcription Pathway
  • Transcriptional regulation of white adipocyte differentiation
  • Nuclear Receptor transcription pathway
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • Ca2+ pathway
  • Signaling by Wnt
  • beta-catenin independent WNT signaling
  • Icosapent
  • Troglitazone
  • Mesalazine
  • Indomethacin
  • Rosiglitazone
  • Nateglinide
  • Sulfasalazine
  • Repaglinide
  • Telmisartan
  • Balsalazide
  • Ibuprofen
  • Glipizide
  • Pioglitazone
  • Mitiglinide
  • Bezafibrate
  • (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
  • 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
  • (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
  • 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
  • (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
  • (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
  • (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
  • (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
  • difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
  • (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
  • 3-(5-methoxy-1H-indol-3-yl)propanoic acid
  • 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
  • (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
  • 2-chloro-5-nitro-N-phenylbenzamide
  • (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
  • 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
  • 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
  • (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
  • 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
  • (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
  • ALEGLITAZAR
PRKCD and PTPN22 protein kinase C, delta protein tyrosine phosphatase, non-receptor type 22 (lymphoid)
  • Ca-dependent events
  • Signaling by GPCR
  • CaM pathway
  • Phospholipase C-mediated cascade
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • Effects of PIP2 hydrolysis
  • Interferon gamma signaling
  • DAP12 signaling
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • G alpha (z) signalling events
  • Role of phospholipids in phagocytosis
  • Fcgamma receptor (FCGR) dependent phagocytosis
  • Signaling by PDGF
  • Calmodulin induced events
  • Regulation of mRNA stability by proteins that bind AU-rich elements
  • Apoptotic cleavage of cellular proteins
  • DAP12 interactions
  • Opioid Signalling
  • EGFR interacts with phospholipase C-gamma
  • Signaling by ERBB2
  • G alpha (q) signalling events
  • Signaling by EGFR
  • GPCR downstream signaling
  • Signaling by VEGF
  • Calmodulin induced events
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Platelet activation, signaling and aggregation
  • G alpha (q) signalling events
  • HuR stabilizes mRNA
  • DAG and IP3 signaling
  • VEGFA-VEGFR2 Pathway
  • CaM pathway
  • VEGFR2 mediated cell proliferation
  • Downstream signaling of activated FGFR
  • Programmed Cell Death
  • Innate Immune System
  • Signalling by NGF
  • PLC beta mediated events
  • Interferon Signaling
  • Apoptotic execution phase
  • Cytokine Signaling in Immune system
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • G-protein mediated events
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by FGFR
  • PLC-gamma1 signalling
PRKCQ and WIPF1 protein kinase C, theta WAS/WASL interacting protein family, member 1
  • G alpha (q) signalling events
  • Signaling by GPCR
  • Downstream TCR signaling
  • Axon guidance
  • Effects of PIP2 hydrolysis
  • FCERI mediated NF-kB activation
  • Inactivation, recovery and regulation of the phototransduction cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • The phototransduction cascade
  • Programmed Cell Death
  • G alpha (z) signalling events
  • Netrin-1 signaling
  • Innate Immune System
  • Apoptotic cleavage of cellular proteins
  • Apoptotic execution phase
  • Diseases associated with visual transduction
  • G alpha (q) signalling events
  • GPCR downstream signaling
  • TCR signaling
  • Visual phototransduction
  • Fc epsilon receptor (FCERI) signaling
  • Platelet activation, signaling and aggregation
  • Adaptive Immune System
  • Fcgamma receptor (FCGR) dependent phagocytosis
  • Regulation of actin dynamics for phagocytic cup formation
  • Innate Immune System
  • Staurosporine
  • Phosphonothreonine
  • Phosphonoserine
PRKCQ and SELL protein kinase C, theta selectin L
  • G alpha (q) signalling events
  • Signaling by GPCR
  • Downstream TCR signaling
  • Axon guidance
  • Effects of PIP2 hydrolysis
  • FCERI mediated NF-kB activation
  • Inactivation, recovery and regulation of the phototransduction cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • The phototransduction cascade
  • Programmed Cell Death
  • G alpha (z) signalling events
  • Netrin-1 signaling
  • Innate Immune System
  • Apoptotic cleavage of cellular proteins
  • Apoptotic execution phase
  • Diseases associated with visual transduction
  • G alpha (q) signalling events
  • GPCR downstream signaling
  • TCR signaling
  • Visual phototransduction
  • Fc epsilon receptor (FCERI) signaling
  • Platelet activation, signaling and aggregation
  • Adaptive Immune System
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
  • Cell surface interactions at the vascular wall
  • Adaptive Immune System
  • Staurosporine
  • Phosphonothreonine
  • Phosphonoserine
PRKCQ and RASGRP3 protein kinase C, theta RAS guanyl releasing protein 3 (calcium and DAG-regulated)
  • G alpha (q) signalling events
  • Signaling by GPCR
  • Downstream TCR signaling
  • Axon guidance
  • Effects of PIP2 hydrolysis
  • FCERI mediated NF-kB activation
  • Inactivation, recovery and regulation of the phototransduction cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • The phototransduction cascade
  • Programmed Cell Death
  • G alpha (z) signalling events
  • Netrin-1 signaling
  • Innate Immune System
  • Apoptotic cleavage of cellular proteins
  • Apoptotic execution phase
  • Diseases associated with visual transduction
  • G alpha (q) signalling events
  • GPCR downstream signaling
  • TCR signaling
  • Visual phototransduction
  • Fc epsilon receptor (FCERI) signaling
  • Platelet activation, signaling and aggregation
  • Adaptive Immune System
  • Signaling by the B Cell Receptor (BCR)
  • Downstream signaling events of B Cell Receptor (BCR)
  • Activation of RAS in B cells
  • Adaptive Immune System
  • Staurosporine
  • Phosphonothreonine
  • Phosphonoserine
PRKCQ and IKBKG protein kinase C, theta inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma
  • G alpha (q) signalling events
  • Signaling by GPCR
  • Downstream TCR signaling
  • Axon guidance
  • Effects of PIP2 hydrolysis
  • FCERI mediated NF-kB activation
  • Inactivation, recovery and regulation of the phototransduction cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • The phototransduction cascade
  • Programmed Cell Death
  • G alpha (z) signalling events
  • Netrin-1 signaling
  • Innate Immune System
  • Apoptotic cleavage of cellular proteins
  • Apoptotic execution phase
  • Diseases associated with visual transduction
  • G alpha (q) signalling events
  • GPCR downstream signaling
  • TCR signaling
  • Visual phototransduction
  • Fc epsilon receptor (FCERI) signaling
  • Platelet activation, signaling and aggregation
  • Adaptive Immune System
  • Signaling by the B Cell Receptor (BCR)
  • Downstream TCR signaling
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • RIP-mediated NFkB activation via ZBP1
  • Toll Like Receptor TLR6:TLR2 Cascade
  • IRAK1 recruits IKK complex
  • Downstream signaling events of B Cell Receptor (BCR)
  • Activated TLR4 signalling
  • Toll Like Receptor TLR1:TLR2 Cascade
  • FCERI mediated NF-kB activation
  • MyD88 cascade initiated on plasma membrane
  • Toll Like Receptor 5 (TLR5) Cascade
  • ZBP1(DAI) mediated induction of type I IFNs
  • NOD1/2 Signaling Pathway
  • MyD88 dependent cascade initiated on endosome
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • MyD88:Mal cascade initiated on plasma membrane
  • Toll Like Receptor 9 (TLR9) Cascade
  • IRAK1 recruits IKK complex
  • JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
  • Innate Immune System
  • activated TAK1 mediates p38 MAPK activation
  • TRIF-mediated TLR3/TLR4 signaling
  • MAP kinase activation in TLR cascade
  • IKK complex recruitment mediated by RIP1
  • Cytosolic sensors of pathogen-associated DNA
  • Cytokine Signaling in Immune system
  • MyD88-independent cascade
  • Toll Like Receptor 2 (TLR2) Cascade
  • Signaling by Interleukins
  • RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
  • TCR signaling
  • Toll-Like Receptors Cascades
  • Toll Like Receptor 10 (TLR10) Cascade
  • Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
  • Activation of NF-kappaB in B cells
  • Toll Like Receptor 3 (TLR3) Cascade
  • Toll Like Receptor 4 (TLR4) Cascade
  • Fc epsilon receptor (FCERI) signaling
  • Interleukin-1 signaling
  • TRAF6 mediated NF-kB activation
  • NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
  • IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • Adaptive Immune System
  • Staurosporine
  • Phosphonothreonine
  • Phosphonoserine
PRKCQ and TAL1 protein kinase C, theta T-cell acute lymphocytic leukemia 1
  • G alpha (q) signalling events
  • Signaling by GPCR
  • Downstream TCR signaling
  • Axon guidance
  • Effects of PIP2 hydrolysis
  • FCERI mediated NF-kB activation
  • Inactivation, recovery and regulation of the phototransduction cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • The phototransduction cascade
  • Programmed Cell Death
  • G alpha (z) signalling events
  • Netrin-1 signaling
  • Innate Immune System
  • Apoptotic cleavage of cellular proteins
  • Apoptotic execution phase
  • Diseases associated with visual transduction
  • G alpha (q) signalling events
  • GPCR downstream signaling
  • TCR signaling
  • Visual phototransduction
  • Fc epsilon receptor (FCERI) signaling
  • Platelet activation, signaling and aggregation
  • Adaptive Immune System
  • Staurosporine
  • Phosphonothreonine
  • Phosphonoserine
PRKCQ and CARD11 protein kinase C, theta caspase recruitment domain family, member 11
  • G alpha (q) signalling events
  • Signaling by GPCR
  • Downstream TCR signaling
  • Axon guidance
  • Effects of PIP2 hydrolysis
  • FCERI mediated NF-kB activation
  • Inactivation, recovery and regulation of the phototransduction cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • The phototransduction cascade
  • Programmed Cell Death
  • G alpha (z) signalling events
  • Netrin-1 signaling
  • Innate Immune System
  • Apoptotic cleavage of cellular proteins
  • Apoptotic execution phase
  • Diseases associated with visual transduction
  • G alpha (q) signalling events
  • GPCR downstream signaling
  • TCR signaling
  • Visual phototransduction
  • Fc epsilon receptor (FCERI) signaling
  • Platelet activation, signaling and aggregation
  • Adaptive Immune System
  • Signaling by the B Cell Receptor (BCR)
  • Downstream signaling events of B Cell Receptor (BCR)
  • TCR signaling
  • FCERI mediated NF-kB activation
  • Downstream TCR signaling
  • Activation of NF-kappaB in B cells
  • Fc epsilon receptor (FCERI) signaling
  • Adaptive Immune System
  • Innate Immune System
  • Staurosporine
  • Phosphonothreonine
  • Phosphonoserine
PRKCQ and GLRX3 protein kinase C, theta glutaredoxin 3
  • G alpha (q) signalling events
  • Signaling by GPCR
  • Downstream TCR signaling
  • Axon guidance
  • Effects of PIP2 hydrolysis
  • FCERI mediated NF-kB activation
  • Inactivation, recovery and regulation of the phototransduction cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • The phototransduction cascade
  • Programmed Cell Death
  • G alpha (z) signalling events
  • Netrin-1 signaling
  • Innate Immune System
  • Apoptotic cleavage of cellular proteins
  • Apoptotic execution phase
  • Diseases associated with visual transduction
  • G alpha (q) signalling events
  • GPCR downstream signaling
  • TCR signaling
  • Visual phototransduction
  • Fc epsilon receptor (FCERI) signaling
  • Platelet activation, signaling and aggregation
  • Adaptive Immune System
  • Staurosporine
  • Phosphonothreonine
  • Phosphonoserine
PRKCQ and YWHAG protein kinase C, theta tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, gamma
  • G alpha (q) signalling events
  • Signaling by GPCR
  • Downstream TCR signaling
  • Axon guidance
  • Effects of PIP2 hydrolysis
  • FCERI mediated NF-kB activation
  • Inactivation, recovery and regulation of the phototransduction cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • The phototransduction cascade
  • Programmed Cell Death
  • G alpha (z) signalling events
  • Netrin-1 signaling
  • Innate Immune System
  • Apoptotic cleavage of cellular proteins
  • Apoptotic execution phase
  • Diseases associated with visual transduction
  • G alpha (q) signalling events
  • GPCR downstream signaling
  • TCR signaling
  • Visual phototransduction
  • Fc epsilon receptor (FCERI) signaling
  • Platelet activation, signaling and aggregation
  • Adaptive Immune System
  • Organelle biogenesis and maintenance
  • Translocation of GLUT4 to the plasma membrane
  • Activation of BH3-only proteins
  • Assembly of the primary cilium
  • G2/M Transition
  • Regulation of PLK1 Activity at G2/M Transition
  • Anchoring of the basal body to the plasma membrane
  • Cell Cycle, Mitotic
  • Activation of BAD and translocation to mitochondria
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Loss of Nlp from mitotic centrosomes
  • Programmed Cell Death
  • Centrosome maturation
  • Mitotic G2-G2/M phases
  • Recruitment of mitotic centrosome proteins and complexes
  • Intrinsic Pathway for Apoptosis
  • Staurosporine
  • Phosphonothreonine
  • Phosphonoserine

Page 29 out of 155 pages